Tresiba FDA Approval History: Complete Regulatory Timeline for Insulin Degludec

What Is Tresiba and Why Did Its FDA Review Take Longer Than Usual?

Tresiba (insulin degludec) is an ultra-long-acting basal insulin analog developed by Novo Nordisk. Its mechanism depends on multi-hexamer formation at the injection site, which produces a slow, steady subcutaneous depot and a flat pharmacokinetic profile with a half-life exceeding 25 hours. That flat profile is clinically significant: head-to-head data show lower rates of nocturnal hypoglycemia compared to insulin glargine U-100 in several randomized trials.

The FDA review took longer than a standard 12-month timeline because of cardiovascular safety concerns that emerged during the agency's evolving post-2008 guidance framework for antidiabetic drugs. Below is the full chronological account.

The 2008 FDA Cardiovascular Safety Guidance

In December 2008, the FDA issued guidance requiring that new antidiabetic agents demonstrate cardiovascular safety, typically through a pre-approval or post-approval cardiovascular outcomes trial (CVOT) showing an upper bound of the 95% confidence interval for the hazard ratio of major adverse cardiovascular events (MACE) below 1.8 pre-approval and below 1.3 post-approval. This guidance, codified in FDA Guidance for Industry (2008), set the framework that directly affected Tresiba's path to market.

Although insulin is not a new chemical entity subject to that guidance in the same way a novel small molecule is, the FDA applied analogous cardiovascular scrutiny to insulin degludec given the at-risk population it would serve.

Initial NDA Submission and the 2013 Complete Response Letter

Novo Nordisk submitted the original NDA for insulin degludec to the FDA in May 2012. The FDA Endocrinologic and Metabolic Drugs Advisory Committee met on November 8, 2012, and voted 8 to 4 that the cardiovascular safety data package at that time was insufficient for approval. Specifically, the committee was concerned that the interim cardiovascular meta-analysis from the Phase 3 program showed a hazard ratio of 1.30 (95% CI: 0.88 to 1.92), with an upper confidence bound exceeding 1.8.

The FDA issued a Complete Response Letter (CRL) in February 2013, requiring Novo Nordisk to conduct a dedicated CVOT before or concurrent with re-submission. That CRL delayed U.S. Availability by more than two years, even though the European Medicines Agency had granted a positive opinion for insulin degludec under the brand name Tresiba in January 2013.

The DEVOTE Trial: Cardiovascular Outcomes Data That Unlocked U.S. Approval

The DEVOTE trial was the cardiovascular outcomes trial the FDA required. It enrolled 7,637 adults with type 2 diabetes at high cardiovascular risk and randomized them 1:1 to insulin degludec or insulin glargine U-100, both titrated to a fasting glucose target of 90 mg/dL or less. DEVOTE was published in the New England Journal of Medicine in 2017.

Primary MACE Endpoint

The primary endpoint was a composite of nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death. Insulin degludec produced a MACE rate of 8.5% vs. 9.3% for insulin glargine U-100 over a median follow-up of 2.0 years. The hazard ratio was 0.91 (95% CI: 0.78 to 1.06), confirming non-inferiority at the pre-specified margin of 1.3. [1]

The trial authors wrote: "Degludec was noninferior to glargine with respect to the incidence of major adverse cardiovascular events in patients with type 2 diabetes who were at high cardiovascular risk." [1]

Severe Hypoglycemia: A Secondary Outcome of Clinical Importance

DEVOTE also reported a 40% lower rate of severe hypoglycemia with insulin degludec compared to insulin glargine U-100 (hazard ratio 0.60, 95% CI: 0.48 to 0.76, P<0.001 for superiority). [1] That finding did not change the NDA outcome directly, since DEVOTE was submitted to support the NDA re-submission prior to full trial completion, but it became central to the approved label's hypoglycemia risk section and to subsequent clinical positioning of the drug.

Regulatory Submission Sequence

Novo Nordisk re-submitted the NDA in mid-2015 with interim DEVOTE data that met the pre-approval upper CI bound of 1.8. The FDA granted approval on September 25, 2015, for:

• Adults with type 1 diabetes mellitus
• Adults with type 2 diabetes mellitus

The 200 U/mL formulation (Tresiba U-200 FlexTouch) was approved simultaneously under NDA 203313, offering a higher concentration option for insulin-resistant patients requiring large basal doses.

The Approved Tresiba Label: Key Prescribing Information

The current prescribing information for Tresiba reflects both the original 2015 approval and subsequent label updates. Clinicians and patients should consult the most recent version at FDA Drugs@FDA for NDA 203314.

Dosing Flexibility Provision

One clinically distinctive feature in the Tresiba label is explicit permission for flexible dosing timing. The label states that Tresiba may be administered at any time of day and that the interval between injections may vary between 8 and 40 hours. No other approved basal insulin in the U.S. Carries that language. This provision emerged directly from Phase 3 flexible-dosing studies (BEGIN Flex, N=687) that randomized patients to intentional dose-time variation and showed non-inferior glycemic control and no increase in hypoglycemia rates compared to fixed once-daily dosing. The BEGIN Flex trial data are registered at ClinicalTrials.gov and summarized in the FDA review documents available at Drugs@FDA.

Contraindications and Warnings

The label carries a boxed warning for hypoglycemia, consistent with all insulins. Key warnings include:

• Never share Tresiba FlexTouch pens, cartridges, or needles between patients even if the needle is changed (risk of bloodborne pathogen transmission).
• Do not mix Tresiba with any other insulin product or diluent.
• Monitor for hypokalemia; insulin drives potassium into cells and can produce life-threatening hypokalemia, particularly when given with potassium-lowering agents.
• Fluid retention and heart failure may occur when insulin is combined with thiazolidinediones (e.g., pioglitazone).

The label also contains specific guidance for patients with renal or hepatic impairment: both conditions may reduce insulin requirements, and more frequent glucose monitoring is recommended. No dose adjustment formula is specified; individual titration applies.

Pediatric Labeling Update (2019)

In 2019, the FDA approved a label expansion allowing Tresiba use in pediatric patients with type 2 diabetes aged 1 year and older. This update was supported by pharmacokinetic and pharmacodynamic data from pediatric trials rather than a full outcomes trial, consistent with FDA pediatric extrapolation policy under the Best Pharmaceuticals for Children Act. The pediatric type 1 diabetes indication was not added at that time; Tresiba is approved for adult type 1 only.

FDA Sentinel and Post-Market Surveillance of Insulin Degludec

The FDA Sentinel System, a national active surveillance network covering more than 100 million patient records from administrative claims and electronic health data, has been used to monitor post-approval safety signals for Tresiba since 2015. As of the most recent publicly available Sentinel analyses, no new safety signals beyond those described in the original label have been formally added to the prescribing information for insulin degludec.

Diabetic Ketoacidosis Risk in Type 1 Diabetes

The FDA's post-market surveillance program pays particular attention to diabetic ketoacidosis (DKA) events in type 1 diabetes patients using basal-only or basal-dominant regimens. With Tresiba, the concern is not unique to the molecule: any ultra-long-acting basal insulin can, if used without adequate bolus coverage, permit rising ketones before hyperglycemia becomes obvious. The current label does not carry a specific DKA warning beyond the standard insulin language, but prescribers initiating Tresiba in type 1 patients should ensure patients understand the signs of DKA and have a clear sick-day management protocol.

FAERS Data and Hypoglycemia Reports

The FDA Adverse Event Reporting System (FAERS) database shows hypoglycemia as the most frequently reported serious adverse event for Tresiba, consistent with the pharmacology of all insulins. The DEVOTE-defined severe hypoglycemia rate of 2.7 events per 100 patient-years with insulin degludec (vs. 4.5 per 100 patient-years with insulin glargine U-100) provides a reference benchmark for real-world expectations. [1]

Comparing the EMA and FDA Approval Timelines

The divergence between EMA and FDA approval dates offers a useful regulatory case study. The EMA issued a positive opinion for Tresiba in January 2013, granting full marketing authorization for type 1 and type 2 diabetes in adults. The agency evaluated the same Phase 3 BEGIN program data but applied a different cardiovascular risk evidentiary standard: the EMA did not require a completed CVOT as a condition of initial approval for basal insulin analogs at that time.

The FDA's more conservative position resulted in a 2.5-year gap in market access between Europe and the United States. Novo Nordisk launched Tresiba commercially in several European countries in 2013 while continuing DEVOTE enrollment to satisfy the U.S. Regulatory requirement. This case illustrates the differential evidentiary thresholds between the two agencies for cardiovascular risk in antidiabetic drugs and has been cited in regulatory science literature as an example of how CVOTs affect time-to-market.

By the time of FDA approval in September 2015, Tresiba had already accumulated approximately two years of real-world European pharmacovigilance data, which the FDA could review as part of the NDA package. That post-marketing European experience did not reveal any new safety signals beyond those seen in the Phase 3 program.

Current Clinical Guidelines and Positioning of Tresiba

The American Diabetes Association (ADA) Standards of Medical Care in Diabetes, updated annually, positions basal insulin analogs (including insulin degludec) as an appropriate option for intensifying therapy when oral agents or GLP-1 receptor agonists are insufficient. The 2024 ADA Standards note that ultra-long-acting insulins (insulin degludec and insulin glargine U-300) may offer lower rates of hypoglycemia compared to first-generation basal analogs in specific patient populations. See the full ADA Standards at

The American Association of Clinical Endocrinology (AACE) 2023 Comprehensive Type 2 Diabetes Management Algorithm similarly includes insulin degludec as a basal insulin option with a notation about its flexible dosing interval as a potential adherence advantage for patients with irregular schedules.

Head-to-Head Data vs. Insulin Glargine U-300

Insulin degludec's main competitor in the ultra-long-acting basal class is insulin glargine U-300 (Toujeo, Sanofi). No adequately powered head-to-head cardiovascular outcomes trial comparing the two agents has been completed. Glycemic and hypoglycemia comparisons in the BRIGHT trial (N=929, randomized, open-label, 24-week) showed similar HbA1c reductions with both agents, but a lower rate of any hypoglycemia during the maintenance period with insulin glargine U-300. The BRIGHT trial was published in Diabetes Care and is indexed at PubMed.

The ADA does not formally prefer one ultra-long-acting agent over another; selection depends on individual patient factors including cost, formulary access, dosing preferences, and hypoglycemia history.

Cost and Formulary Access

The wholesale acquisition cost (WAC) of Tresiba in the United States has been a barrier for some patients. Novo Nordisk offers a patient assistance program, and in March 2023, the company announced a 78% list price reduction across its insulin portfolio as part of a broader industry pricing shift. The FDA's drug pricing resources and labeling documents are the most current source for NDA-specific information, though formulary and pricing data require direct verification with insurers.

Tresiba Label Revisions: A Timeline of Post-Approval Changes

The Tresiba prescribing information has been revised multiple times since 2015. Key changes include:

• 2016: Minor labeling revisions to the Medication Guide clarifying pen-sharing risks following FDA-wide safety communication on insulin pen reuse.
• 2017: Label updated to incorporate final DEVOTE trial cardiovascular data following full publication. The cardiovascular outcomes section of the label was expanded with DEVOTE hazard ratio data and the severe hypoglycemia finding. [1]
• 2019: Pediatric type 2 diabetes indication added for patients aged 1 year and older.
• 2020: Updated Medication Guide language per FDA standardized format requirements for insulin products.
• 2023: Incorporation of updated hypoglycemia risk communication consistent with FDA's insulin class labeling harmonization initiative.

Each revision followed the standard Prior Approval Supplement or Changes Being Effected supplement pathway under 21 CFR 314.70. Prescribers should always reference the current label at Drugs@FDA (NDA 203314) rather than package inserts distributed at the time of original dispensing.

Practical Prescribing Considerations Derived Directly from the Regulatory Record

The regulatory history of Tresiba carries direct clinical implications. The FDA's requirement for DEVOTE data before approval means the cardiovascular safety evidence base for insulin degludec in high-risk type 2 diabetes patients is actually stronger than for many earlier basal insulins that were approved before the 2008 CVOT guidance existed.

Starting Dose Guidance from the Label

For insulin-naive patients with type 2 diabetes, the label recommends starting at 10 units once daily, then titrating by 2 units every 3 to 4 days to achieve the target fasting glucose. For patients transferring from another basal insulin on a unit-to-unit basis, the label notes that some patients may require a dose adjustment after transfer, and that the flexible dosing window (8 to 40 hours) begins only after an adequate steady state is reached, which requires approximately 3 to 4 days given the ultra-long half-life.

Renal and Hepatic Impairment

No specific dose adjustment is mandated by the label for renal or hepatic impairment, but both conditions can prolong the effective duration of action and reduce clearance of insulin. The label states: "Glucose monitoring should be intensified and the insulin degludec dose adjusted on an individual basis." Patients with a GFR below 30 mL/min/1.73m² or with Child-Pugh class B or C cirrhosis warrant more conservative titration and closer follow-up.

Drug Interactions

Beta-blockers, clonidine, and guanethidine may blunt the sympathetic response to hypoglycemia and mask tachycardia as an early warning sign. Thiazolidinediones combined with any insulin can cause fluid retention and exacerbate heart failure. Alcohol may potentiate the hypoglycemic effect of insulin degludec by inhibiting hepatic gluconeogenesis. These interactions are detailed in Section 7 of the current Tresiba prescribing information.